Sort   by:  
 Page size 
ProteomicsMultiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma
Fourteen LGSOC cell lines were interrogated using whole exome sequencing, RNA sequencing, and mass spectrometry-based proteomics. Somatic mutation, copy-number aberrations, gene and protein expression were analyzed and integrated using different computational approaches. LGSOC cell line data was com...
ORGANISM(S): Homo sapiens (Human) 
2021-05-17 | PXD019544 | Pride
Tmt Ovarian carcinoma 
UnknownPressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial.
Not available
S-EPMC11324501 | biostudies-literature
UnknownContemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Not available
S-EPMC12073492 | biostudies-literature
ProteomicsQuantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.
Low-grade serous ovarian carcinoma (LGSOC) is a rare and largely chemoresistant subtype of epithelial ovarian cancer. Unlike treatment for high-grade serous ovarian cancer (HGSOC), management options for LGSOC patients are limited, in part, due to a lack of deep molecular characterization of this di...
ORGANISM(S): Homo sapiens (Human) 
2025-09-30 | PXD050642 | Pride
Low-grade serous ovarian cancer High-grade serous ovarian cancer Lgsoc Fallopian tube Hgsoc Quantitative proteomics 
TranscriptomicsGene expression profile of tumor cells from primary tumors, ascites and metastases of low grade serous ovarian cancer patients
Differ from the aggressive nature of HGSOC (high grade serous ovarian cancer), LGSOC (low grade serous ovarian cancer) is characterized by an early age of disease onset, slow growth pattern, and poor response to chemotherapy. To understand more specifically the underlying gene profiling discrepancy ...
ORGANISM(S): Homo sapiens 
2017-12-19 | GSE73091 | GEO
ProteomicsA preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment
Background: Long-term drug evaluation heavily relies upon rodent models. Drug discovery methods to reduce animal models in oncology may include three-dimensional (3D) cellular systems that take into account tumor microenvironment (TME) cell types and biomechanical properties. Methods: In this study...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD039590 | Pride
3d cancer model  long-term  drug evaluation  pre-clinical  micro-environment  stiffness 
OtherScreen1 VOA6406gain-of-function meki-resistance data
Gain and loss of function genome wide CRISPR/Cas9 screens in LGSOC cell lines to identify genes that modulate response to MEK inhibitor trametinib
ORGANISM(S): Homo sapiens 
2022-09-21 | GSE213580 | GEO
Methylation profilingIdentification of Therapeutic Targets for Low-Grade Serous Ovarian Carcinoma [EM-seq]
Low-grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor ...
ORGANISM(S): Homo sapiens 
2026-03-30 | GSE314295 | GEO
TranscriptomicsIdentification of Therapeutic Targets for Low-Grade Serous Ovarian Carcinoma
Low-grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor ...
ORGANISM(S): Homo sapiens 
2026-03-30 | GSE313802 | GEO
OtherA Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low--Grade Serous Carcinoma
Purpose: Neoadjuvant chemotherapy shows limited activity in low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, and peritoneum (LGSOC). Given LGSOC’s similarities to hormone receptor- positive (HR+) breast cancer, including clinical benefit from endocrine therapies, we conducted a phase...
ORGANISM(S): synthetic construct Homo sapiens 
2026-03-12 | GSE292946 | GEO
Sort   by:  
 Page size